Andrés José Maria Ferreri


Affiliation: San Raffaele Scientific Institute
Country: Italy


  1. Citterio G, Reni M, Ferreri A. Present and future treatment options for primary CNS lymphoma. Expert Opin Pharmacother. 2015;16:2569-79 pubmed publisher
    ..Management of intraocular and meningeal lymphomas is controversial considering their peculiar characteristics that need to be specifically addressed. Finally, management of elderly patients and of relapsed disease is addressed. ..
  2. request reprint
    Ferreri A, Dell Oro S, Foppoli M, Bernardi M, Brandes A, Tosoni A, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology. 2006;66:1435-8 pubmed
    ..Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained. ..
  3. Ferreri A, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30:2988-94 pubmed publisher
    ..Lymphoma regression is consequent to Cp eradication, which can easily be monitored on conjunctival and blood samples. Prospective trials aimed at identifying more effective administration schedules for doxycycline are warranted. ..
  4. Ferreri A, Sassone M, Kiesewetter B, Govi S, Scarfò L, Donadoni G, et al. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015;26:1760-5 pubmed publisher
    ..HD-K is a safe and active salvage treatment in EMZL patients. This macrolide deserves to be further investigated in EMZL and other lymphoma categories. ..
  5. Ferreri A, Donadoni G, Cabras M, Patti C, Mian M, Zambello R, et al. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. J Clin Oncol. 2015;33:3903-10 pubmed publisher
    ..The combination of high doses of antimetabolites, R-HDS, and ASCT is feasible and effective in patients age 18 to 70 years old with secondary CNS lymphoma, and we propose it as a new standard therapeutic option. ..
  6. Ferreri A, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi L, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217-27 pubmed publisher
    ..Associazione Italiana del Farmaco, Cancer Research UK, Oncosuisse, and Swiss National Foundation. ..
  7. Scarfo L, Ferreri A, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-82 pubmed publisher
    ..e., monoclonal B-cell lymphocytosis, MBL), defined new prognostic and predictive markers, improving patient stratification, but also broadened the therapeutic armamentarium with novel agents, targeting fundamental signaling pathways. ..
  8. Ferreri A, Sassone M, Zaja F, Re A, Spina M, Rocco A, et al. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lancet Haematol. 2017;4:e137-e146 pubmed publisher
    ..These results warrant further investigation of immunomodulatory drugs as maintenance in high-risk patients with DLBCL. Celgene Corp. ..
  9. Sassone M, Ponzoni M, Ferreri A. Ocular adnexal marginal zone lymphoma: Clinical presentation, pathogenesis, diagnosis, prognosis, and treatment. Best Pract Res Clin Haematol. 2017;30:118-130 pubmed publisher
    ..Novel agents and chemotherapy-free strategies are being investigated to reduce side effects and improve tumor control. This review is focused in recent knowledge improvements in this lymphoma. ..

More Information


  1. Ferreri A, Cwynarski K, Pulczynski E, Fox C, Schorb E, La Rosée P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extrano. Lancet Haematol. 2017;4:e510-e523 pubmed publisher
    ..The risks and implications of cognitive impairment after WBRT should be considered at the time of therapeutic decision. Agenzia Italiana del Farmaco, Cancer Research UK, Oncosuisse, and Swiss National Science Foundation. ..